Durable Efficacy of Alemtuzumab in Relapsing-Remitting Multiple Sclerosis Patients Who Participated in the CARE-MS Studies: Three Year Follow-Up

被引：0

作者：

Fox, Edward ^{[1
]}

Arnold, Douglas ^{[2
]}

Cohen, Jeffrey ^{[3
]}

Coles, Alasdair ^{[4
]}

Confavreux, Christian ^{[5
]}

Hartung, Hans ^{[6
]}

Havrdova, Eva ^{[7
]}

Selmaj, Krzysztof ^{[8
]}

Weiner, Howard ^{[9
]}

Twyman, Cary ^{[10
]}

Vladic, Anton ^{[11
]}

Margolin, David ^{[12
]}

Oyuela, Pedro ^{[12
]}

Panzara, Michael ^{[12
]}

Compston, Alastair ^{[13
]}

机构：

[1] Univ Texas Med Branch, Round Rock, TX USA

[2] McGill Univ, Montreal, PQ, Canada

[3] Cleveland Clin, Solon, OH USA

[4] Addenbrookes Hosp, Cambridge, England

[5] Univ Lyon 1, F-69365 Lyon, France

[6] Univ Dusseldorf, Dusseldorf, Germany

[7] Charles Univ Prague, Sch Med 1, Prague, Czech Republic

[8] Klin J Katedra Neurol Akad, Lodz, Poland

[9] Brigham & Womens Hosp Ctr, Boston, MA USA

[10] Associates Neurol, Lexington, KY USA

[11] Sveti Duh Gen Hosp, Zagreb, Croatia

[12] Genzyme Corp, Cambridge, MA USA

[13] Univ Cambridge, Cambridge, England

来源：

NEUROLOGY | 2013年 / 80卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

S41001

引用

页数：2

共 50 条

[1] Reduction of disability with alemtuzumab in relapsing remitting multiple sclerosis patients who participated in CARE-MS II: three year follow-up
Hartung, H. -P.
Arnold, D. L.
Cohen, J. A.
Coles, A. J.
Fox, E. J.
Havrdova, E.
Selmaj, K. W.
Weiner, H. L.
Palmer, J.
Margolin, D. H.
Panzara, M. A.
Compston, D. A. S.
MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (11) : 250 - 250
[2] Durable Effect of Alemtuzumab on Relapse Outcomes in Patients with Relapsing-Remitting Multiple Sclerosis: CARE-MS Three-Year Follow-Up
Broadley, S. A.
Arnold, D. L.
Cohen, J. A.
Coles, A. J.
Fox, E. J.
Hartung, H-P
Havrdova, E.
Selmaj, K. W.
Weiner, H. L.
Palmer, J.
Margolin, D. H.
Panzara, M. A.
Compston, D. A. S.
MULTIPLE SCLEROSIS JOURNAL, 2014, 20 (07) : 934 - 935
[3] Adverse event profile of alemtuzumab in active relapsing remitting multiple sclerosis patients who participated in the CARE-MS studies: three-year follow-up
Lycke, J.
Arnold, D. L.
Cohen, J. A.
Coles, A. J.
Fox, E. J.
Hartung, H. -P.
Havrdova, E.
Selmaj, K. W.
Weiner, H. L.
Palmer, J.
Margolin, D. H.
Oyuela, P.
Panzara, M. A.
Compston, D. A. S.
MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (11) : 487 - 488
[4] Autoimmunity in patients treated With Alemtuzumab for relapsing-remitting multiple sclerosis: 5-Year follow-up of the CARE-MS studies.
Dayan, C.
Cuker, A.
LaGanke, C.
Fernandez, O.
Hupperts, R. M. M.
Sharrack, B.
Singer, B.
Vermersch, P.
Margolin, D. H.
Chou, E.
Twyman, C. L.
MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 51 - 52
[5] Alemtuzumab improves MRI outcomes in relapsing-remitting multiple sclerosis patients who relapsed on prior therapy: three-year follow-up of CARE-MS II
Fisher, E.
Barkhof, F.
Cohen, J. A.
Fox, E. J.
Selmaj, K. W.
Margolin, D. H.
Palmer, J.
Arnold, D. L.
MULTIPLE SCLEROSIS JOURNAL, 2014, 20 : 113 - 114
[6] Alemtuzumab Improves Brain MRI Outcomes in Patients With Active Relapsing-Remitting Multiple Sclerosis: 3-Year Follow-up of the CARE-MS Studies
Arnold, Douglas
Cohen, Jeffrey
Barkhof, Frederik
Selmaj, Krzysztof
Margolin, David
Palmer, Jeffrey
Fox, Edward
NEUROLOGY, 2014, 83 (02) : E35 - E36
[7] Durable efficacy of alemtuzumab in CARE-MS II patients with highly active relapsing-remitting multiple sclerosis: 4-year outcomes
Krieger, S.
Freedman, M. S.
Moreau, T.
Havrdova, E.
Selmaj, K. W.
Margolin, D. H.
Kasten, L.
MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 573 - 573
[8] Durable reduction of disability with alemtuzumab in treatment-naive relapsing-remitting multiple sclerosis patients: 3-year follow-up of the CARE-MS I study
Wiendl, H.
Palmer, J.
Margolin, D. H.
EUROPEAN JOURNAL OF NEUROLOGY, 2014, 21 : 683 - 683
[9] Durable reduction of disability with alemtuzumab in treatment-naive relapsing-remitting multiple sclerosis patients: 3-year follow-up of the CARE-MS I study
Wiendl, H.
Palmer, J.
Margolin, D. H.
JOURNAL OF NEUROLOGY, 2014, 261 : S442 - S443
[10] Efficacy and safety of alemtuzumab in patients with relapsing-remitting MS who relapsed on prior therapy: four-year follow-up of the CARE-MS II study
Hartung, H-P
Arnold, D. L.
Cohen, J. A.
Coles, A. J.
Fox, E. J.
Havrdova, E.
Selmaj, K. W.
Margolin, D. H.
Palmer, J.
Oyuela, P.
Panzara, M. A.
Compston, D. A. S.
MULTIPLE SCLEROSIS JOURNAL, 2014, 20 : 85 - 86

← 1 2 3 4 5 →